MedTrace Logo

Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer

NCT03979911 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2019-06-07

No results posted yet for this study

Summary

This retrospective study evaluated the efficacy and the safety of use of this treatment combined with a taxane for the treatment of HER2-positive metastatic breast cancer and compared the clinical and demographic characteristics of real life patients to the patients of CLEOPATRA.

Conditions

  • Breast Neoplasms
  • HER-2 Gene Amplification

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2019-07-22
Completion
2019-07-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03979911 on ClinicalTrials.gov